학술논문
Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer: Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS, Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Cougar Biotechnology, Los Angeles, CA
Document Type
Short Survey
Author
Source
In Urologic Oncology: Seminars and Original Investigations 2009 27(6):690-691
Subject
Language
ISSN
1078-1439